Results 121 to 130 of about 14,520 (202)

Capivasertib for locally advanced or metastatic breast cancer. [PDF]

Aust Prescr
europepmc   +1 more source

From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2- breast cancer. [PDF]

Breast
Stachyra P, Hernando Meliá C, López-Guerrero JA, Gavilá Gregori J, Guerrero-Zotano ÁL.   +4 more
europepmc   +1 more source

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial. [PDF]

ESMO Open
Curigliano G, O'Shaughnessy J, Bidard FC, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, Carey LA, Okera M, Melo E, Zagouri F, Magallanes-Maciel M, Karadurmus N, Bahadur S, Speck RM, Wang XA, Pradhan K, Macey J, Kitchen H, Fairhurst S, Miller J, Jhaveri KL, Harbeck N.   +23 more
europepmc   +1 more source

Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling. [PDF]

Nat Commun
Fernandez KJ, Sultani G, Nobis M, Gloss B, Eshraghi L, McCart Reed AE, Alexandrou S, Lee C, Roden DL, Jones EI, Simad MH, Millar EKA, Bartonicek N, Oakes SR, Valdes-Mora F, Colino-Sanguino Y, Mok ETY, Williams HL, Kutasovic JR, Cummings MC, Stoehr J, Lee V, Harvey K, Wu S, Lakhani SR, Simpson PT, Cox TR, Ooms LM, Mitchell CA, Salomon R, Swarbrick A, Gallego-Ortega D, Lim E, Timpson P, Caldon CE.   +34 more
europepmc   +1 more source

Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy. [PDF]

Front Med (Lausanne)
Peng X, Chang W.
europepmc   +1 more source

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. [PDF]

J Clin Oncol
Hurvitz SA, Layman RM, Curigliano G, André F, Cristofanilli M, Kim SB, Martínez Rodríguez JL, Nadal JC, Kim GM, Lo L, Remolina-Bonilla YA, Rosselli G, Emile G, Korbenfeld E, Puig JM, Wesolowski R, Martin M, Ring A, Han HS, Giordano A, Mutka SC, Moss K, Suzuki S, Sullivan B, Gorbatchevsky I, Pistilli B, VIKTORIA-1 Study Group.   +26 more
europepmc   +1 more source

Distinct 2-phenylimidazo[1,2-<i>a</i>]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligands. [PDF]

iScience
Koellisch K, Blattner C, Motta S, Wesslowski J, Rothley M, Büchel S, Sirounian S, Segatto I, Weber HT, Müller J, Grimaldi M, Stober J, Wammetsberger Z, Pan M, Houtman R, Grathwol CW, Lin LW, Buluwela L, Kolluri SK, Mytzka D, Ali S, Jung N, Balaguer P, Thaler S, Belletti B, Bonati L, Bourguet W, Bräse S, Davidson G, Cato ACB.   +29 more
europepmc   +1 more source

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice. [PDF]

Breast
Rugo HS, Curigliano G, Cescon DW, Penault-Llorca F, Harbeck N, Im SA, Park YH, Barrios C, Modi S, Tolaney SM, Oliveira M.   +10 more
europepmc   +1 more source

<i>ESR1</i> mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception. [PDF]

Explor Target Antitumor Ther
Martinez T, Wegner S, Bahmad HF.
europepmc   +1 more source

Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer. [PDF]

Int J Mol Sci
Iguchi E, Watanabe M, Kobayashi K, Boku S, Nishio W, Kato C, Morita M, Sakaguchi K, Mutoh M, Kameda T, Naoi Y.   +10 more
europepmc   +1 more source